Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Apolipoprotein B (ApoB)—containing lipoproteins more closely identifies atherosclerosis and correlates to atherogenic particles in circulation.

This episode will:

The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.

Date: 9/10/24

Speaker(s): Maeson Latsko, PhD

Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD

Additional Resources:

Quest Diagnostics Clinical Education Center [Link]

Ordering information: Apolipoprotein B | Test Detail | Quest Diagnostics

Apolipoprotein B | Test Summary | Quest Diagnostics

Apo B and cardiovascular risk | Quest Diagnostics | Quest Diagnostics

References:

Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ: Cardiovascular Quality and Outcomes. 2011;4(3):337-345. doi:10.1161/CIRCOUTCOMES.110.959247

Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625

Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356